Jennifer Hamner, DO
Urogynecology and Reconstructive Pelvic Surgery · Carmel, INNPI 1841417110
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.9%), travel and lodging and grants — rather than concentrated in one kind of arrangement. Axonics, Inc. accounts for 70.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $2,249 and has fallen 97.1% since, to $65 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in IN, where the typical reported total is $5,227.
Across 33 payments — averaging $101.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- Coloplast$348
- Boston Scientific$297
- Medtronic$167
- Astellas Pharma US Inc$114
- Caldera Medical, Inc$38
- plus $25 from 1 others
What the payments were for
- Grants$1244%
- Travel & lodging$1,25037%
- Food & beverage$1,96759%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 18 | $2,353 |
| Coloplast | 3 | $348 |
| Boston Scientific | 6 | $297 |
| Medtronic(2 entities) | 3 | $167 |
| Astellas Pharma US Inc | 1 | $114 |
| Caldera Medical, Inc | 1 | $38 |
| Laborie Medical Technologies Corp. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$1,795
- ALTIS$256
- GENERAL FEMALE SUI$124
- MYRBETRIQ$114
- Bulkamid$100
How this compares
$3,341 in reported general payments places this provider in the 35th percentile of 21 urogynecology and reconstructive pelvic surgery providers in Indiana.
See all urogynecology and reconstructive pelvic surgery providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 355 | $250,188 |
| MyrbetriqMirabegron | 93 | $49,711 |
| Estradiol | 364 | $24,855 |
| PremarinEstrogens, Conjugated | 27 | $12,097 |
| EstringEstradiol | 21 | $10,708 |
| Mirabegron ErMirabegron | 17 | $5,956 |
| Trimethoprim | 16 | $1,086 |
| YuvafemEstradiol | 12 | $811 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 61 | $721 |
| Clobetasol Propionate | 11 | $492 |
| Trospium Chloride | 15 | $399 |
| NitrofurantoinNitrofurantoin Macrocrystal | 91 | $202 |
| Cephalexin | 42 | $187 |
| Fluconazole | 11 | $62 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $114 | $49,71193 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 21 urogynecology and reconstructive pelvic surgery providers in Indiana.
Other urogynecology and reconstructive pelvic surgery in Carmel
- Kathryn CopelandCarmel$26K
- Sameena RaoCarmel$3K
- Alexander HubbCarmel$2K
- Cindy BasinskiNewburgh$132K
- Jeffrey BlakeNoblesville$15K
- Ted RothSouth Bend$14K
- Krystine GulbrandDanville$13K
- Hussein WardaGreenwood$10K
- Amanda LaporteIndianapolis$9K
- Martina MutoneFishers$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.